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Background: The complement system is part of the immune system in acute coronary syndrome (ACS). Adiponectin
has anti-atherogenic and anti-inflammatory properties. Adiponectin and C1q form a protein complex in blood, and
serum C1q binding adiponectin (C1q-APN) can be measured. We investigated the comparative evaluation of serum
C1q-APN levels in males with ACS, stable angina pectoris (SAP) versus controls.
Methods: The study subjects were 138 Japanese patients who underwent diagnostic coronary angiography. Blood
total adiponectin (Total-APN), C1q-APN and C1q were measured by enzyme-linked immunosorbent assays. Patients
were divided into three groups according to the clinical condition: ACS (n = 78), SAP (n = 41) or normal coronary (NC,
n = 19) groups.
Results: Serum C1q levels were significantly higher in the ACS group (54.9±1.2 μg/mL) than in the NC group (48.0±2.5
μg/mL). Although serum Total-APN levels were significantly lower in the SAP and ACS groups, compared with the NC
group (7.0±0.5, 7.2±0.3, 10.6±2.0 μg/mL, respectively), serum C1q-APN levels were significantly higher in the ACS group
than in the NC and SAP groups (112.1±4.1, 66.3±4.4, 65.7±2.9 units/mL, respectively).
Conclusions: Patients with ACS had higher serum C1q-APN levels.
Trial Registration: UMIN000002997
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Disruption of atherosclerotic plaques with associated
thrombus is responsible for the majority of the acute
coronary syndrome (ACS). Plaque instability is related
closely to the degree of inflammation. The complement
system plays a part of role in acute phase ACS [1]. Adi-
ponectin, an adipocyte-derived blood protein [2] is
present abundantly in injured arteries [3,4] and has anti-
inflammatory, anti- atherosclerotic properties [5,6] and
anti-diabetic property [7,8]. Low levels of total-adiponectin
(Total-APN) have been reported in patients with coronary
artery disease (CAD), including angina and ACS [9-15].
Adiponectin circulates in blood in three major forms: tri-
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stated.[16]. However, the main form of blood adiponectin remains
to be elucidated. We reported recently that adiponectin
binds with C1q in human blood, and also developed a sys-
tem to measure human serum C1q-binding adiponectin
(C1q-APN) [17]. Serum C1q-APN/Total-APN ratio is a
novel marker of the metabolic syndrome in male subjects
[17]. Serum C1q-APN/Total-APN ratio correlated with poly-
vascular diseases and stable CAD in type 2 diabetics [18,19].
However, the characteristics of C1q-APN in ACS patients re-
main unclear. The aim of the present study was to clarify the
comparative evaluation of serum C1q-APN levels in males
with ACS, stable angina pectoris (SAP) versus controls.Methods
Participants
The study (#UMIN000002997) subjects were consecutive
138 Japanese admitted-patients who underwent diagnostic
coronary angiography for suspected CAD following chest
pain and/or ischemic changes on the electrocardiogram,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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computed tomography scan for measurement of adipose
tissues that was classified to visceral and subcutaneous
fat tissue compartment at Kokura Memorial Hospital,
Kenporen Osaka Central Hospital and Department of
Metabolic Medicine, Osaka University Hospital between
April and September 2009. Patients who had major surgery
or trauma, serious active infectious diseases, malignancies,
and chronic inflammatory diseases including rheumatoid
arthritis, osteoarthritis, and inflammatory bowel disease
were excluded from the study. Patients treated with pioglit-
azone, which is known to increase serum levels of Total-
APN [20] and C1q-APN [21], and those with renal dysfunc-
tion (creatinine >1.5 mg/dL) [22] were also excluded from
the study. The Medical Ethics Committees of Osaka Uni-
versity, Kenporen Osaka Central Hospital and Kokura Me-
morial Hospital approved the study.
Patients were divided into three groups according to the
clinical condition: ACS [acute myocardial infarction (AMI),
unstable angina pectoris (UAP)], SAP and normal coronary
group (NC). All coronary angiograms were evaluated by at
least two experienced examiners. Patients of the ACS group
comprised those with AMI or UAP, and included 68 pa-
tients with AMI, who underwent catheterization within 24
hours of the onset of chest pain. The diagnosis of AMI was
based on clinical symptoms, ST segment elevation (STEMI)
on the electrocardiogram with non-ST segment elevation
acute myocardial infarction (NSTEMI), coronary angio-
graphic findings (occlusion of main coronary artery branch
with thrombolysis in myocardial infarction (TIMI) grade
flow of 0, 1, or 2), and changes in serum creatine kinase
concentrations (more than twofold increase from the upper
limit of the normal range). STEMI was diagnosed when
new or presumed new ST-segment elevation of at least
0.1 mV in two or more leads was observed in any lead or
new left bundle branch block was found on the index or
qualifying electrocardiogram with 1 positive cardiac bio-
chemical marker of necrosis. NSTEMI was diagnosed in
the presence of 1 positive cardiac biochemical marker of
necrosis without new ST-segment elevation seen on the
index or qualifying electrocardiogram. UAP was diagnosed
in 10 patients, based on clinical symptoms, namely typical
precordial chest pain of class IIB or IIIB in the Braunwald
classification, angiographic evidence (documented severe
stenosis of 75% according to the American Heart Associ-
ation classification in one or more major coronary artery),
and changes in serum creatine kinase concentrations (no
significant evidence of increase). SAP, which was observed
in the remaining 41 patients, was diagnosed based on
clinical symptoms, specifically typical precordial chest
pain associated with exercise-induced cardiac ischemia
and coronary angiographic findings (documented severe
stenosis of 75% according to the American Heart Asso-
ciation classification, in one or more major coronary artery).The reference group consisted of 19 control participants
(without CAD).
Anthropometry and laboratory tests
Anthropometric variables [height and weight] were mea-
sured in the standing position and body mass index (BMI)
was calculated [=weight (kg) / height (m)2]. Visceral fat area
(VFA) and subcutaneous fat area (SFA) were measured
manually on computed tomography scan at the umbilical
level according to our laboratory methods [23]. Systolic and
diastolic blood pressures were measured with a standard
mercury sphygmomanometer on the left or right arm in
the supine position after at least 10-minute rest.
Venous blood samples were collected in the morning
after overnight fast for measurement of serum creatinine,
lipids, glucose, and HbA1c (Japan Diabetes Society [JDS])
at next day of admission (NC and SAP groups) and about
1 week after onset of ACS (ACS group). The value of
HbA1c (%) was estimated as the National Glycohemoglo-
bin Standardization Program (NGSP) equivalent value
(%), calculated by the formula HbA1c (%) =HbA1c (JDS,
%) + 0.4%. For the purpose of the present study, serum
samples that were obtained at baseline from each partici-
pant were stored promptly at −20°C. After thawing the
samples, serum levels of Total-APN and high-molecular
weight-adiponectin (HMW-APN) were measured by
enzyme-linked immunosorbent assay (ELISA) kits (Hu-
man adiponectin ELISA kit, Human HMW-adiponectin
ELISA kit, Otsuka Pharmaceutical Co. Tokushima, Japan)
[2,16]. Serum levels of C1q-APN (units (U) /mL) and C1q
(μg/mL) were measured by our in-house ELISA, as re-
ported previously by our group [17]. The intra- and inter-
coefficients of variation (CV) for C1q-APN ELISA are
below 4.6% and 6.7%, respectively. The intra- and inter-
CV for C1q ELISA are below 4.6% and 5.0%, respectively.
Hypertension was defined as systolic blood pressure
≥140 mmHg, and/or diastolic blood pressure ≥90 mmHg,
or current treatment for hypertension. Diabetes mellitus
was defined according to the World Health Organization
criteria, or non-fasting plasma glucose concentration ≥126
mg/dL, and/or current treatment for diabetes mellitus.
Dyslipidemia was defined as low-density lipoprotein-
cholesterol concentration of ≥140 mg/dL, triglyceride
concentration ≥150 mg/dL, high-density lipoprotein-
cholesterol concentration <40 mg/dL, and/or treatment
for dyslipidemia.
Statistical analysis
Data are presented as mean±SEM. Differences in frequen-
cies were examined by the χ2 test. Differences among
groups were compared by one- or two-way analysis of
variance (ANOVA) with Fisher's protected least significant
difference test for multiple-group analysis. In all cases, p
values <0.05 were considered statistically significant. All
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ery Software 9.0 (SAS Institute, Cary, NC).
Results
Characteristics of all patients
Table 1 summarizes the characteristics of the participating
subjects. The affected coronary artery was the left main
coronary artery (LMCA) in 2 patients, left anterior de-
scending artery (LAD) in 64 patients, left circumflex artery
(LCX) in 20 patients and right coronary artery (RCA) in
33 patients. Single and multiple vessel disease was identi-
fied in 86% (none/single/double/triple = 19/72/32/15).
Comparison of adiponectin parameters among NC, SAP
and ACS groups
Table 1 shows the characteristics of patients without CAD,
with SAP and those with ACS. There were no significantTable 1 Baseline characteristics of the subjects enrolled in th
All
Number 138
Age, years 65 ± 1 (40–86)
Body mass index, kg/m2 24.3 ± 0.3 (17.7-38
Visceral fat area, cm2 117 ± 5 (25–223)
Subcutaneous fat area, cm2 130 ± 5 (22–361)
Smoking (none-/ex-/current-smoker), n 45/32/61




Hypertension, n 92 (67%)
calcium channel antagonists/angiotensin receptor
blockers /β-blockers/diuretics, n
44/70/62/9
Dyslipidemia, n 61 (44%)
Statins/fibrates/ezetimibe/cholestimide, n 83/2/1/1
anti-platelet drugs (aspirin/ticlopidine/clopidogrel), n 115/32/65
Family history of CAD, n 13 (9%)
Systolic blood pressure, mmHg 138 ± 2 (90–217)
Diastolic blood pressure, mmHg 83 ± 1 (49–146)
Hemoglobin A1c (NGSP), % 6.7 ± 0.1 (3.4-12.2
LDL-C, mg/dL 112 ± 3 (20–250)
Triglyceride, mg/dL 122 ± 7 (24–611)
HDL-C, mg/dL 49 ± 1 (26–128)
Creatinine, mg/dL 0.85 ± 0.03 (0.47-1
Target lesions (LMCA/LAD/LCX/RCA), n 2/64/20/33
Vessels (None/SVD/DVD/TVD), n 19/72/32/15
Procedures (PCI/CABG), n 118/1
Data are mean ± SEM (range), or number of subjects analyzed. *P < 0.05, Compared
Compared with the SAP group.
Differences among groups were compared by one- or two-way analysis of variance (A
analysis. Differences in frequencies were examined by the χ2 test. CAD, Coronary artery
lipoprotein-cholesterol; LMCA, Left main coronary artery; LAD, Left anterior descending
disease; DVD, Double vessels disease; TVD, Triple vessels disease; PCI, Percutaneous codifferences in age, BMI, VFA and SFA between the three
groups, which is known to influence serum levels of Total-
APN [2] and C1q-APN [17]. Subjects with SAP had higher
prevalence of current smoke, hypertension, dyslipidemia,
than those with NC. Serum HDL-C levels were significantly
lower in the ACS group, compared with the NC and SAP
groups. Serum Total-APN levels were significantly lower in
the SAP (7.0±0.5 μg/mL) and ACS (7.2±0.3) groups, com-
pared with the NC group (10.6±2.0, Figure 1a). Serum
HMW-APN levels were significantly lower in the SAP
group (4.1±0.5 μg/mL) and trended to be lower in ACS
group (4.9±0.4), compared with the NC group (6.8±1.6,
Figure 1b). Serum C1q-APN levels were significantly
higher in ACS group (112.1±4.1 U/mL) compared with
the NC (66.3±4.4) and SAP group (65.7±2.9, Figure 1c).
Serum C1q levels were significantly higher in the ACS
group (54.9±1.2 μg/mL), compared with the NC groupe present study
NC group SAP group ACS group
19 41 78
65 ± 2 (51–79) 65 ± 1 (49–81) 65 ± 1 (40–86)
.4) 24.3 ± 1.0 (19.5-32.5) 24.6 ± 0.6 (17.7-31.2) 24.2 ± 0.4 (17.8-38.4)
101 ± 13 (25–223) 125 ± 10 (17–277) 116 ± 6 (18–259)
124 ± 15 (45–329) 142 ± 8 (50–224) 126 ± 7 (22–361)
9/5/5 14/10/17* 22/17/39
10 (53%) 29 (71%) 30 (38%)
5/0/1/2/2 10/5/8/2/2 7/0/1/16/2
15 (79%) 27* (66%) 50 (64%)
7/2/2/0 21/20/4/4 16/48/56/5
7 (37%) 24* (59%) 30 (38%)
10/1/0/0 10/0/1/1 63/1/0/0
6/0/4 31/0/20 78/32/41
2 (11%) 3* (7%) 8 (10%)
139 ± 4 (108–173) 138 ± 3 (100–175) 138 ± 3 (90–217)
79 ± 2 (64–94) 75 ± 2 (49–99) 87 ± 2 (57–146)†
) 7.3 ± 0.4 (5.8-9.8) 6.9 ± 0.2 (5.5-10.1) 6.6 ± 0.2 (3.4-12.2)
114 ± 8 (58–154) 107 ± 6 (49–197) 115 ± 4 (20–250)
124 ± 16 (49–263) 140 ± 12 (59–374) 113 ± 10 (24–611)
63 ± 4 (39–95) 53 ± 3 (27–104) 44 ± 2 (26–128)¶,†




with the NC group, ¶P < 0.0001, Compared with the NC group, †P < 0.001,
NOVA) with Fisher's protected least significant difference test for multiple-group
disease; HDL-C, High-density lipoprotein-cholesterol; LDL-C, Low-density
artery; LCX, Left circumflex artery; RCA, Right coronary artery; SVD, Single vessel





















































































































































Figure 1 Circulating levels of (a) Total-APN, (b) HMW-APN, (c) C1q-APN, (d) C1q, (e) HMW-APN/Total-APN, (f) C1q-APN/Total-APN,
(g) C1q-APN/C1q, and (h) Total-APN/C1q in subjects without CAD (Normal coronary; NC), stable angina pectoris (SAP) and acute coronary
syndrome (ACS). Differences among groups were compared by one- or two-way analysis of variance (ANOVA) with Fisher's protected least
significant difference test for multiple-group analysis.
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in serum HMW-APN/Total-APN ratio among the three
groups (ACS: 0.60±0.04, SAP: 0.55±0.04, NC: 0.63±0.03,
Figure 1e). Serum C1q-APN/Total-APN ratio was signifi-
cantly higher in the ACS group (17.50±0.83), compared
with the NC (7.96±0.81) and SAP (10.95±0.89, Figure 1f)
groups. Serum C1q-APN/Total-APN ratio was signifi-
cantly higher in the SAP group than in the NC group
(Figure 1f ) Serum C1q-APN/C1q ratio was significantly
higher in the ACS group (2.11±0.09), compared with the
NC (1.28±0.05) and SAP (1.45±0.16, Figure 1g) groups.
Serum Total-APN/C1q ratio was significantly lower in the
SAP (0.15±0.01) and ACS (0.14±0.01) groups, compared
with the NC group (0.25±0.07, Figure 1h).
Discussion
The following were the major findings of the present
study: 1) serum C1q-APN levels were higher in the ACSgroup than in the NC and SAP groups, 2) serum C1q
levels were higher in the ACS group than in the NC
group, and 3) serum C1q-APN/Total-APN ratio was
higher in the SAP and ACS groups, compared with the
NC group.
This is the first report of significantly higher serum
C1q levels in patients with ACS compared with the con-
trol (Figure 1d). The complement system is part of the
immune system in acute phase ACS [1]. C1q interacts
with complement cell-surface receptor to promote phago-
cytosis and local pro-inflammatory response [24]. Patho-
gen associated molecular pattern (PAMP) recognized and
bound by defense collagens, such as C1q, leads to rapid
containment of infection via complement activation [25].
The inflammatory response is also mediated by the
patient's innate immune cells including adipocyte apoptosis,
which are equipped with pattern recognition receptors.
These receptors are able to sense injury-induced, damage-
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collection, processing, and storage of blood/blood compo-
nents [26]. These systems may promote the formation of
acute and chronic phase of atherosclerosis.
On the other hand, adiponectin shows structural hom-
ology to collagen VIII, X and complement factor C1q [3]
and belongs to soluble defense collagen family [27]. Peake
et al. reported that adiponectin bound C1q in vitro, which
induces activation of the classical complement pathway
[28]. Adiponectin have been shown to facilitate enhanced
phagocytosis and modulate induction of cytokines towards
an anti-inflammatory profile and protect against cardiovas-
cular diseases [29]. Adiponectin increases the expression of
tissue inhibitor of metalloproteinase-1 in macrophages [30],
thus may inhibit matrix degradation in atheromatous pla-
ques. In the present study, hypoadiponectinemia was de-
tected in patients with ACS and SAP (low serum Total-
APN levels) (Figure 1a), in agreement with several previous
studies [10-15]. We recently reported that serum C1q-
APN/Total-APN ratio correlated with the metabolic syn-
drome in men [17], and with polyvascular diseases and
CAD in type 2 diabetics [18,19], although there was no sig-
nificant difference in serum C1q-APN levels between pa-
tients without and with CAD. The present study also
showed no significant difference in serum C1q-APN levels
between NC and SAP groups. Interestingly, the present
study demonstrated that serum C1q-APN levels were 1.7-
fold higher in patients with ACS than those of the NC and
SAP groups (Figure 1c). The ACS groups had significantly
lower serum HDL-C levels, than the NC and SAP groups
(Table 1). Our previous report had reported that stepwise
multiple regression analysis did not identify HDL-C as a
significant determinant of C1q–APN [17]. Some studies re-
ported that serum complement levels were markedly ele-
vated in ACS compared with SAP patients, suggesting an
acute phase and inflammatory response [31,32]. The pro-
tein family CTRPs (C1q/TNF-related proteins) has recently
been identified as adiponectin paralogs and some CTRP
members share adiponectin's metabolic regulatory function
and regulate cardiac remodeling after acute myocardial in-
farction [33,34]. These results suggest that adiponectin
seems to have a protective role in activated complement
system in the development of ACS and have an impact on
the self-defense system through its binding with C1q in
blood. Measurements of serum Total-APN plus C1q-APN
may become instrumental to combat ACS. However, to
date, the precise value of serum C1q-APN cannot be mea-
sured, because the proportion of blood adiponectin that
forms protein complex with C1q remains unclear. Further
clinical and experimental studies are needed to clarify the
role of adiponectin and C1q network in ACS.
In conclusion, the present study indicates that serum
C1q-APN levels were higher in male patients with ACS,
and that serum C1q-APN/Total-APN ratio was higherin male patients with SAP and ACS than the control.
Serum C1q-APN might be a promising target in at-
tempts to reduce ACS.
Study limitations
The present study has several limitations. First, this is a
cross-sectional study, making it difficult to establish a
cause-effect relationship. Further prospective studies
should be conducted to analyze this relationship. Sec-
ond, all patients in this study were Japanese men and
any differences from other ethnic groups are unknown.
All participants were Japanese and each gave a written
informed consent. Based upon 80% power to detect
statistically significant differences (p = 0.05; two-sided)
as our group reported previously [18,19], a sample size
of at least 20 patients in each group was required to
demonstrate (total sample size = 60). Further multicen-
ter studies that include larger samples of subjects, es-
pecially those of other races, are needed. Finally, we
measured various laboratory parameters and fat distri-
bution at about one week after onset of ACS, therefore,
medical therapy for ACS may have affected these pa-
rameters [35].
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